Trials / Completed
CompletedNCT00130871
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
Detailed description
Levosimendan or placebo infusion is started at the time of induction of anesthesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | levosimendan |
Timeline
- Start date
- 2004-01-01
- Completion
- 2006-01-01
- First posted
- 2005-08-16
- Last updated
- 2007-02-21
Locations
2 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT00130871. Inclusion in this directory is not an endorsement.